Available Until 4/8/2024
VIEW CART

Existing and Emerging Clostridioides difficile Infection Therapies: Importance of Microbiome Restoration

Content Release Date: 2/8/2023
Expiration Date: 4/8/2024
Activity Type: Application-based
CE Credits: up to 2.5 contact hours (0.25 CEUs)
Activity Fee:  Free

Activity Overview

Clostridioides difficile infection (CDI) is a threat to public health and recurrence is common. This educational activity will review the burden of CDI on the health system and the logistical complexities of existing and emerging therapeutics.  Current guideline recommendations for the treatment of primary and recurrent CDI will be reviewed. The activity will conclude with a discussion of existing and emerging strategies for the treatment of patients with recurrent CDI, including the role of microbiome restoration. 

This course consists of three activities (see table below) and provides up to 2.50 hours of continuing pharmacy education credit.  

Part 1: 

Existing and Emerging Clostridioides difficile Infection Therapies: Importance of Microbiome Restoration* 

This 1.5-hour online educational activity reviews existing and emerging therapeutics for recurrent Clostridioides difficile infection (CDI), the role of microbiome restoration in CDI, and the logistical complexities of integrating these therapeutics into the health system.  

 

Part 2: 
Ask the Experts: Safety and Efficacy of Microbiome-Targeted Therapies for the Prevention of C. difficile**

Clostridioides difficile infection (CDI) is a threat to public health and recurrence is common. Treatment options for recurrent CDI continue to evolve to include non-antibiotic therapies, including fecal microbiota transplantation (FMT). With increasing evidence of the relationship between dysbiosis and gastrointestinal and metabolic diseases, FMT has been developed to focus on microbiome repair for the treatment of recurrent CDI. This educational activity will address the safety and efficacy of traditional FMT and other live biotherapeutic products.

Engaging the Experts Podcasts

Tune in for additional insights and perspectives

from our faculty experts.
CE Credits: 1.5 hours CE Credits: 1.00 hours CE Credits: none

*Please note, this activity was presented live on December 6, 2022 as part of the ASHP 2022 Midyear Clinical Meeting & Exhibition. You can only claim credit once for this activity; live or home study 

**Please note, this activity was presented live on March 8, 2023 via webinar. You can only claim credit once for this activity; live or home study.

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

The target audience for this educational activity is pharmacists who practice in hospitals, health systems, and ambulatory clinics as well as transitions of care pharmacists who care for or are interested in the care of patients with recurrent CDI.  

After participating in this CPE activity, learners should be able to:

Existing and Emerging Clostridioides difficile Infection Therapies: Importance of Microbiome Restoration 

ACPE Number: 0204-0000-22-424-H01-P

  • Compare recently released guideline recommendations for the treatment of CDI in adults.
  • Evaluate existing and emerging therapeutic strategies for the treatment of recurrent CDI.
  • Explain the implementation challenges of microbiome restoration strategies in patients with recurrent CDI.  

Ask the Experts: Safety and Efficacy of Microbiome-Targeted Therapies for the Prevention of C. difficile

ACPE Number: 0204-0000-23-401-H01-P

  • Differentiate probiotics from traditional fecal microbiota transplantation (FMT) and other live biotherapeutic products (LBPs).
  • Summarize the existing safety and efficacy data for probiotics, traditional FMT, and other LBPs.
  • Choose an appropriate microbiome-targeted therapy for the prevention of C. difficile infection.

Travis J. Carlson, PharmD, BCIDP 
Assistant Professor 
High Point University 
High Point, North Carolina 




Travis J. Carlson, PharmD, BCIDP, is Assistant Professor, High Point University, Fred Wilson School of Pharmacy in High Point, North Carolina. Dr. Carlson received his Pharm.D. from Drake University and completed his PGY-1 residency at Aurora St. Luke’s Medical Center in Milwaukee, Wisconsin, and his Infectious Diseases Fellowship at Baylor St. Luke’s Medical Center in conjunction with the University of Houston College of Pharmacy in Houston, Texas. 


Kelly R. Reveles, PharmD, PhD, BCPS, BCIDP 
Associate Professor, College of Pharmacy 
The University of Texas at Austin 
San Antonio, Texas 





Dr. Kelly Reveles is an Associate Professor at The University of Texas at Austin College of Pharmacy and an Adjoint Associate Professor at UT Health San Antonio. She received her Doctor of Pharmacy degree from UT Austin in 2010 and her Translational Science PhD degree from UT Austin in 2014. Dr. Reveles’ current research involves clinical and translational sciences focused on the prevention and treatment of Clostridioides difficile infection and the use of microbiome-targeted therapies to prevent infection and other aging-related conditions. 

The following persons in control of this activity’s content have relevant financial relationships:

  • Travis J. Carlson, PharmD, BCIDP: Merck - research grant

  • Kelly R. Reveles, PharmD, PhD, BCPS: Ferring Pharmaceuticals - consultant, Speaker's Bureau  

All other persons in control of content do not have any relevant financial relationships with an ineligible company.  

As defined by the Standards of Integrity and Independence in Accredited Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity.

Activities can be completed in any order. Each activity consists of audio and video, and an evaluation. Learners must review all content and complete an evaluation to receive continuing education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned – no exceptions! To verify that you have completed the required steps and to ensure your credits have been reported to CPE Monitor, we encourage you to check your NABP eProfile account to validate your credits were transferred successfully before the ACPE 60-day deadline. After the 60 day deadline, ASHP will no longer be able to award credit for this activity.

Provided by ASHP
Supported by an educational grant from Ferring Pharmaceuticals Inc.